These findings suggest that JAK-STAT and NF-κB pathways may serve as potential therapeutic targets in ESCC, such as through JAK or NF-κB inhibitors to modulate HLA-II expression and enhance anti-tumor immunity. Here, NFKB1 is linked to esophageal squamous cell carcinoma.